PMID- 22517709
OWN - NLM
STAT- MEDLINE
DCOM- 20120926
LR  - 20220321
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 17
IP  - 1
DP  - 2012 Jan-Mar
TI  - Effects on the immune system and toxicity of carboplatin/paclitaxel combination 
      chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer 
      and its role in survival and toxicity.
PG  - 143-8
AB  - PURPOSE: To examine the impact of paclitaxel and carboplatin combination 
      chemotherapy on the parameters of the immune system in patients with non small 
      cell lung cancer (NSCLC) and with ovarian cancer before, during and after 
      chemotherapy, and the effect of this combination on the overall patient survival. 
      METHODS: 24 patients with NSCLC and 20 with ovarian cancer (all in stage IIIb-IV) 
      treated with 6 courses of paclitaxel and carboplatin combination chemotherapy 
      were separated into two groups according to their survival group A: long survival 
      (> 12 months for NSCLC; > 30 months for ovarian cancer) group B: short survival 
      (<12 months for NSCLC; <30 months for ovarian cancer). At the same time we 
      studied some immunological parameters (CD3, CD4, CD8, CD56, CD34, IL-3, IFN-gamma) in 
      relation with the induced toxicity during chemotherapy. The results were analysed 
      using the ANOVA method. RESULTS: We observed a statistically significant 
      difference of CD4 and CD4/CD8 after chemotherapy between groups A and B (p<0.001 
      and p< 0.006 respectively), implying that the further increase of T-helper cells 
      after chemotherapy had a positive impact on survival. In addition, statistically 
      interesting was the difference in values of IFN-gamma between patients of groups A 
      and B before and after chemotherapy (p< 0.039 and p< 0.027, respectively). 
      Patients with high IL-3 had little chance of toxicity. CONCLUSION: Our findings 
      support that with carboplatin/ paclitaxel combination chemotherapy, important 
      parameters of the immune system (IFN-gamma, CD4, CD4/CD8) can be used as prognostic 
      factors for survival, while others (IL-3) as indicators of toxicity.
FAU - Hatziveis, K
AU  - Hatziveis K
AD  - Laboratory of Pharmaceutical Chemistry, Department of Pharmacy, Faculty of 
      Pharmacy, School of Health Sciences, University of Patras, Greece. 
      khatziveis@gmail.com
FAU - Tourlakis, D
AU  - Tourlakis D
FAU - Hountis, P
AU  - Hountis P
FAU - Kyriazanos, I
AU  - Kyriazanos I
FAU - Sougleri, M
AU  - Sougleri M
FAU - Ginopoulos, P
AU  - Ginopoulos P
FAU - Camoutsis, C
AU  - Camoutsis C
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Interleukin-3)
RN  - 82115-62-6 (Interferon-gamma)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Immune System/*drug effects
MH  - Interferon-gamma/blood
MH  - Interleukin-3/blood
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*drug therapy/mortality/pathology
MH  - Paclitaxel/administration & dosage/adverse effects
EDAT- 2012/04/21 06:00
MHDA- 2012/09/27 06:00
CRDT- 2012/04/21 06:00
PHST- 2012/04/21 06:00 [entrez]
PHST- 2012/04/21 06:00 [pubmed]
PHST- 2012/09/27 06:00 [medline]
PST - ppublish
SO  - J BUON. 2012 Jan-Mar;17(1):143-8.